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Technetium-99mmethoxy isobutyl isonitrile (99mTc-MIBI; sestamibi) single-photon emission computed
tomography (SPECT)/computed tomography (CT) performed for preoperative localization of parathyroid
adenomas or for other indications can reveal incidentalomas. Interpretation of such findings can be
challenging, particularly when thyroid or other endocrine tumors are also present. Preoperative staging
of a 59-year-old female patient with medullary thyroid carcinoma (MTC) showing moderate hyper-
metabolism on 18F-fluorodeoxyglucose positron emission tomography/CT also detected a slightly hy-
permetabolic pulmonary nodule (standardized uptake value normalized by bodyweightmax=2.0 g/mL).
A sestamibi SPECT/CT performed because of concomitant primary hyperparathyroidism showed in-
creased uptake by both the MTC and the pulmonary nodule, raising suspicion of MTCmetastasis. Lung
wedge resection biopsy revealed a sclerosing pneumocytoma (SPC), a rare benign pulmonary tumor not
previously known to retain sestamibi. In contrast to classical knowledge that sestamibi uptake by
tumors is associatedwith its retention bymitochondria, immunohistochemical analyses showed that the
mitochondrial content of the patient’s SPC was low. This case illustrates the behavior of SPC in ses-
tamibi scintigraphy and indicates that SPC is a potential cancer mimicker in this setting.
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Technetium-99mmethoxy isobutyl isonitrile (99mTc-MIBI; sestamibi) single-photon emission
computed tomography (SPECT)/computed tomography (CT) is a high-accuracy modality for
the localization of parathyroid adenomas [1]. Incidental findings are frequent during ses-
tamibi scans and mainly include nodular uptake in the thyroid gland. The presence of a
thyroid nodule with a sestamibi-hot and 99mTc-cold phenotype is suspicious for malignancy
andmaywarrant fine-needle aspiration before parathyroid adenoma resection. Interestingly,
sestamibi imaging has also shown potential for predicting malignancy of pulmonary lesions
with high (.80%) sensitivity and specificity, as confirmed by a recent meta-analysis [2];
therefore, some experts have suggested this imaging modality as a potential alternative to
18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/CT, particularly in
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countries where access to the latter is limited because of higher costs. We present the case of a
female patient diagnosed with medullary thyroid carcinoma (MTC) and primary hyper-
parathyroidism, in whom pulmonary metastasis was suspected in part because of increased
sestamibi uptake by a pulmonary nodule, similar to the primary MTC lesion. Lung wedge
resection biopsy showed sclerosing pneumocytoma (SPC), a rare benign pulmonary tumor
whose biological behavior on sestamibi scintigraphy has never been reported.
1. Case Presentation
A 59-year-old Caucasian female underwent 18F-FDG PET/CT for follow-up of invasive lo-
calized breast cancer, previously treated by surgery and adjuvant radiotherapy. A 13-mm
nodule was detected in the right lung, exhibiting slight FDG uptake (standardized uptake
value normalized by body weight max = 2.0 g/mL) (Fig. 1A). A moderately hypermetabolic
(standardized uptake value normalized by body weight max = 3.7 g/mL) 14-mm nodule was
also visualized in the upper left thyroid lobe (Fig. 1B). Increased levels of serum calcitonin
(377 ng/L) and carcinoembryonic antigen (CEA) (16.6 mg/L) suggested MTC, subsequently
Figure 1. 18F-FDG PET/CT and 99mTc-MIBI SPECT/CT images. (A) 18F-FDG PET/CT
performed for staging of a resected localized breast cancer revealed a slightly hypermetabolic
right pulmonary lesion (arrow). (B) 18F-FDG PET/CT also showed two cervical sites of focal
uptake, one in the upper pole of the left thyroid lobe (red arrow) and the other posterior
to the lower pole of the right thyroid lobe (white arrowhead), confirmed on histology to
correspond to MTC and parathyroid adenoma, respectively. (C, D) On sestamibi SPECT/CT
imaging, both (C) the pulmonary lesion (white arrow) and (D) the fine-needle aspiration
cytology‒confirmed MTC (red arrow) exhibited increased uptake, as did the right parathyroid
adenoma (white arrowhead).
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confirmed by fine-needle aspiration cytology. Family history was notable for breast and
colorectal cancer in different second-degree relatives from the paternal side but was negative
for MTC, primary hyperparathyroidism, and pheochromocytoma. While awaiting the results
of germline RET gene sequencing for type 2 multiple endocrine neoplasia (MEN2) syndrome,
biochemical screening excluded pheochromocytoma but revealed primary hyperparathy-
roidism. Cervical ultrasonography and sestamibi SPECT/CT (extending to the level of
the chest and the upper abdomen to detect any potential ectopic parathyroid adenomas)
localized a right inferior parathyroid adenoma. Both the fine-needle aspiration cytology‒
confirmedMTC (Fig. 1D) and the pulmonary nodule (Fig. 1C) exhibited increased 99mTc-MIBI
uptake. Surgical resection of the pulmonary nodule was thus proposed to exclude MTC
pulmonary metastasis, even though solitary MTC pulmonary metastasis is rarely seen in the
absence of cervical lymph node involvement. Histopathologic analysis of the excised nodule
revealed SPC, a rare benign pulmonary tumor (Fig. 2).
After exclusion of pulmonary metastasis of MTC, total thyroidectomy and prophylactic
central neck lymph node dissection were performed, along with resection of the parathyroid
adenoma. Interestingly, the thyroid specimen did not reveal histologic signs in favor or
MEN2; notably, there was no C-cell hyperplasia. Biochemical response was rapid, with
normalization of serum calcitonin and CEA levels. Sequencing of the RET and BRCA-1/
BRCA-2 genes on genomic DNA extracted from peripheral blood did not reveal pathogenic
Figure 2. Histologic images of the pulmonary lesion. (A) The pulmonary lesion was
predominantly solid with round and atypical spindle stromal cells. Focally, epithelial cells
with papillary growth pattern and areas of sclerosis were present. (B) Cytokeratin (CK)
immunostaining was positive only in the epithelial cells. (C) Thyroid transcription factor 1
immunostaining showed nuclear reactivity in both stromal and epithelial cells, a typical
finding in SPC. Similar to CK, napsin A was expressed only in epithelial cells (not shown).
(D) Immunostaining for mitochondrial antigen [3] showed relatively poor mitochondrial
content in neoplastic cells. Scale bar = 100 mm.
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alterations. For the RET gene in particular, polymerase chain reaction and sequencing of
coding exons 5, 8, 10, 11, and 13 to 16 and the respective splicing regions were performed
(reference sequence NG_007489.1, LRG_518t1), according to published guidelines and local
practices. At 1-year follow-up, the patientwas disease freewith undetectable serum calcitonin
level, normal serum CEA level (,5 mg/L), and no suspicious cervical lymph nodes on ul-
trasonography. Primary hyperparathyroidism resolved as well, and the breast cancer con-
tinues to be in complete remission.
2. Discussion
Sestamibi imaging, initially implemented for cardiac scintigraphy, has become a mainstay of
the preoperative localization of parathyroid adenomas, frequently allowing for targeted,
minimally invasive surgery, as well as offering the ability to localize ectopic adenomas or
diagnose multiglandular disease [1]. Additional interest has been drawn to its potential for
predicting malignancy of thyroid and pulmonary lesions. For instance, a direct comparison of
sestamibi SPECT/CT vs 18F-FDG PET/CT in a prospective study showed similar accuracy in
the diagnosis of pulmonary malignancies [4]. Moreover, the use of sestamibi SPECT for
staging of thyroid malignancies has been suggested for differentiated thyroid carcinoma [5]
and interestingly also for MTC, with better performance than conventional CT in the as-
sessment of neck and chest involvement during staging for recurrentMTC [6]. In this context,
the sestamibi-positive pulmonary lesion of our patient warranted excision biopsy to exclude
MTC metastasis; however, histopathologic examination showed SPC, a rare benign tumor
previously known as sclerosing hemangioma [7].
SPC typically presents as a solitary incidental nodule, mostly asymptomatic and with
predominant incidence in women (female/male ratio, 5:1). Incidental diagnosis of SPC in
various radiologic and nuclear medicine studies has been recently reported [8]. SPC usually
demonstrates low-to-moderate hypermetabolism on 18F-FDG PET, as was the case in our
patient, with uptake proportional to tumor size. To the best of our knowledge, there are no
previous reports on the behavior of SPC on sestamibi imaging. Although false-positive
findings of sestamibi uptake in pulmonary nodules have been described, data on the exact
histopathologic nature of the misleading lesions are scarce. In one of the few publications
providing detailed reports of benign lesions with sestamibi uptake [9], the majority (9 of 10)
were infectious (abscesses, tuberculosis, hydatid cysts) or inflammatory (granulomatosis)
lesions, with only one benign tumor (hamartoma). Discovery of an SPC in this setting has
never been reported.
In addition, we attempted to clarify the mechanism of increased sestamibi avidity of SPC.
Sestamibi is a lipophilic, cationic isonitrile compound that diffuses passively across cell
membranes. Because of its negative transmembrane potential, it is primarily sequestered in
the mitochondria and thereby trapped intracellularly. Mitochondria-rich oxyphil cells have
accounted for the increased retention of sestamibi by parathyroid adenomas [1]. Thus, we
hypothesized that the avidity of the patient’s SPC for sestamibi would be linked to a high
mitochondrial content. The latter was previously documented in the cytoplasm of epithelial
(surface) cells of four SPCs studied with electron microscopy [10]. Nevertheless, immuno-
staining using a monoclonal antimitochondrial antigen antibody [3] revealed a rather low
mitochondria content in the patient’s SPC (Fig. 2D). Alternatively, increased vascularity of
SPC may explain its avidity to sestamibi. In support of this hypothesis, studies assessing the
role of sestamibi in the investigation of myocardial ischemia have shown that its uptake is
indeed proportional to blood flow [11].
On the basis of RET gene sequencing results, which included all the coding exons rec-
ommended by the latest American Thyroid Association guidelines [12], we concluded that
the patient most probably had sporadic MTC. This conclusion was also supported by the
negative family history for MEN2 manifestations, the absence of C-cell hyperplasia in the
patient’s thyroid, and the relatively advanced age of the patient for a first manifestation of
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MEN2-associated MTC. Thus, we believe that a phenocopy is more likely than a mutation in
another region of theRET gene or amutation in another unknown gene associated withMTC.
In conclusion, endocrinologists and nuclear medicine physicians should be aware that
sestamibi imaging can be accompanied by incidental pulmonary findings, which can raise
suspicion of metastasis in the context of MTC, whether sporadic or associated with MEN2.
SPC is a rare but increasingly reported cancer mimicker in this context, and it should be
considered in the differential diagnosis along with inflammatory and infectious processes.
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